Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2945063 | 0.96 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| SCHEMBL6938267 | 0.95 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| Bromide SCHEMBL3963512 | 0.82 | GSK3A (0.43) | ALDH1A1MAPTSMN1; SMN2RAB9AKMT2A | |
| SCHEMBL6936500 | 0.80 | GSK3A (0.44) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| Bromide SCHEMBL3851561 | 0.71 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| Bromide SCHEMBL2947798 | 0.71 | RAB9A (0.46) | ALDH1A1HAO1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL6938200 | 0.70 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| SCHEMBL6935144 | 0.69 | GSK3B (0.44) | ALDH1A1HAO1MAPTSMN1; SMN2RAB9A | |
| Bromide SCHEMBL2956997 | 0.69 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| Bromide SCHEMBL3845993 | 0.68 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009051804-A1 | THIAZOLIUM COMPOUNDS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH INSULIN RESISTANCE | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009042213-A1 | METHODS OF TREATING OR PREVENTING CARDIAC DISEASE ASSOCIATED WITH A HIGH FAT DIET | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009023207-A1 | THIAZOLIUM COMPOUNDS FOR TREATING GASTROINTESTINAL COMPLICATIONS | SYNVISTA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | CERAMI ANTHONY | 2008-06-05 | — | — | US | disclosed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | ALDH1A1 653/4885HAO1 2323/4885MAPT 2404/4885 |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | ALDH1A1 1227/4885HAO1 909/4885MAPT 1062/4885 |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | ALDH1A1 1576/4885HAO1 1048/4885MAPT 1385/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | ALDH1A1 1227/4885HAO1 909/4885MAPT 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.